Trypanosoma cruzi, a flagellate
protozoan parasite, is responsible for Chagas disease. The parasite
major cysteine protease, cruzain (Cz), plays a vital role at every
stage of its life cycle and the active-site region of the enzyme,
similar to those of other members of the papain superfamily, is well
characterized. Taking advantage of structural information available
in public databases about Cz bound to known covalent inhibitors, along
with their corresponding activity annotations, in this work, we performed
a deep analysis of the molecular interactions at the Cz binding cleft,
in order to investigate the enzyme inhibition mechanism. Our toolbox
for performing this study consisted of the charge density topological
analysis of the complexes to extract the molecular interactions and
machine learning classification models to relate the interactions
with biological activity. More precisely, such a combination was useful
for the classification of molecular interactions as “active-like”
or “inactive-like” according to whether they are prevalent
in the most active or less active complexes, respectively. Further
analysis of interactions with the help of unsupervised learning tools
also allowed the understanding of how these interactions come into
play together to trigger the enzyme into a particular conformational
state. Most active inhibitors induce some conformational changes within
the enzyme that lead to an overall better fit of the inhibitor into
the binding cleft. Curiously, some of these conformational changes
can be considered as a hallmark of the substrate recognition event,
which means that most active inhibitors are likely recognized by the
enzyme as if they were its own substrate so that the catalytic machinery
is arranged as if it is about to break the substrate scissile bond.
Overall, these results contribute to a better understanding of the
enzyme inhibition mechanism. Moreover, the information about main
interactions extracted through this work is already being used in
our lab to guide docking solutions in ongoing prospective virtual
screening campaigns to search for novel noncovalent cruzain inhibitors.